



(51) International Patent Classification:

A61K 47/68 (2017.01) C07D 495/22 (2006.01)
C07D 491/22 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2024/092145

(22) International Filing Date:

10 May 2024 (10.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/093976
12 May 2023 (12.05.2023) CN
PCT/CN2023/117368
07 September 2023 (07.09.2023) CN
PCT/CN2023/120684
22 September 2023 (22.09.2023) CN

(71) Applicant: **BIOCYTOGEN PHARMACEUTICALS
(BEIJING) CO., LTD.** [CN/CN]; No.12, Baoshen South

Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN).

(72) Inventors: **SHEN, Yuelei**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry, Daxing District, Beijing 102600 (CN). **YANG, Yi**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry, Daxing District, Beijing 102600 (CN). **SHANG, Chengzhang**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry, Daxing District, Beijing 102600 (CN). **ZHANG, Lei**; Room 406, Floor 4, Building 1, No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: LINKER COMPOUNDS AND LIGAND-DRUG CONJUGATES, PREPARATION METHODS AND USES THEREOF




FIG. 2

(57) Abstract: Provided are novel linker compounds and ligand-drug conjugates, and more specifically to linker compounds comprising a short polypeptide and use thereof in preparation of ligand-drug conjugates, ligand-drug conjugates comprising the linker, and preparation and use thereof. The novel linker compounds improve the coupling efficiency of the ligand-drug conjugates as well as the homogeneity and overall stability of the conjugates, further improving the efficacy and safety of the ligand-drug conjugates.

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))